肾脏疾病与卒中:流行病学及易感性的潜在机制
综述指出慢性肾脏病(CKD)患者缺血性与出血性卒中风险均升高,急性肾损伤(AKI)与卒中后死亡和不良功能结局相关;CKD患者接受溶栓和取栓的机会似乎较少,溶栓后脑出血风险增加40%、死亡风险增加20%;尿毒症毒素等非传统危险因素可能通过增加血脑屏障通透性和凝血/血栓机制受损促进卒中。
要点
- CKD患者缺血性与出血性卒中风险均高于一般人群,终末期肾病(ESKD)缺血性与出血性卒中发生率分别增加7倍和9倍。
- 卒中患者中AKI发生率为12%,与死亡风险增加4倍及不良功能结局相关。
- CKD患者接受溶栓和取栓等血运重建技术的机会似乎较少,尽管其预后更差。
核心结论
- CKD患者缺血性与出血性卒中风险均升高,急性与慢性肾功能损害均独立关联卒中后不良结局。
- CKD患者接受血运重建技术的机会似乎较少,溶栓后CKD与脑出血风险增加40%、死亡风险增加20%及更差功能神经结局相关,取栓后CKD与脑出血无关但仍与死亡风险增加相关。
- 格列净类对卒中预防的有益影响仍不确定,尿毒症毒素等非传统危险因素可能通过增加血脑屏障通透性和凝血/血栓机制受损促进CKD卒中,需临床前和临床研究专门评估这些非传统危险因素对卒中发生率和结局的影响。
研究设计与样本
- 综述,未报告系统检索范围。
主要发现
- ESKD与缺血性和出血性卒中发生率分别增加7倍和9倍相关,神经结局更差,死亡风险增加3倍。
- 卒中患者中AKI发生率为12%,与死亡风险增加4倍和不良功能结局相关。
- 溶栓后CKD与脑出血风险增加40%、死亡风险增加20%和更差功能神经结局相关。
- 取栓后CKD与脑出血无关,但仍与死亡风险增加相关,AKI与不良结局和死亡相关。
- 格列净类对卒中预防的有益影响仍不确定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with chronic kidney disease (CKD) have an increased risk of both ischaemic and haemorrhagic stroke compared with the general population. Both acute and chronic kidney impairment are independently associated with poor outcome after the onset of a stroke, after adjustment for confounders. End-stage kidney disease (ESKD) is associated with a 7- and 9-fold increased incidence of both ischaemic and haemorrhagic strokes, respectively, poorer neurological outcome and a 3-fold higher mortality. Acute kidney injury (AKI) occurs in 12% of patients with stroke and is associated with a 4-fold increased mortality and unfavourable functional outcome. CKD patients seem to have less access to revascularisation techniques like thrombolysis and thrombectomy despite their poorer prognosis. Even if CKD patients could benefit from these specific treatments in acute ischaemic stroke, their prognosis remains poor. After thrombolysis, CKD is associated with a 40% increased risk of intracerebral haemorrhage (ICH), a 20% increase in mortality and poorer functional neurological outcomes. After thrombectomy, CKD is not associated with ICH but is still associated with increased mortality, and AKI with unfavourable outcome and mortality. The beneficial impact of gliflozins on the prevention of stroke is still uncertain. Non-traditional risk factors of stroke, like uraemic toxins, can lead to chronic cerebrovascular disease predisposing to stroke in CKD, notably through an increase in the blood-brain barrier permeability and impaired coagulation and thrombosis mechanisms. Preclinical and clinical studies are needed to specifically assess the impact of these non-traditional risk factors on stroke incidence and outcomes, aiming to optimize and identify potential therapeutic targets.
引用
- Bobot M, Suissa L, Hak JF, et al. Kidney disease and stroke: epidemiology and potential mechanisms of susceptibility. Nephrol Dial Transplant. 2023. PMID: 36754366. doi:10.1093/ndt/gfad029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。